{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/ATRA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Atara Biotherapeutics, Inc. (NASDAQ: ATRA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Atara Biotherapeutics, Inc., listed on NASDAQ under ticker ATRA, with ISIN US0465132068 and LEI 549300WBXUXZRE03MS38. Its security type is Corporate, its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States, Delaware. Segment is not on the record. Status: listed, not halted.\n\n## The disclosure read\n\nThe record holds 69 filings in the twelve months to 2026-11-08, across 40 filing days. The median gap between filing days is 3 days. Days from the latest filing to the record date are 65; the latest filing is dated 2026-09-04 and is of type directors_dealings. The NASDAQ exchange median is 52 filings, a median cadence gap of 6.0 days, and a median latency of 5.0 days. The sector median is 65.5 filings, a median cadence gap of 5.5 days, and a median latency of 4.0 days.\n\n## Auditor\n\nThe auditor of record is DELOITTE & TOUCHE LLP, located in San Francisco, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name-change lines. Domicile change is not on the record: EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record: the exchanges' tier transfers are not EDGAR filings. Halt flag: listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe field was found. The issuer's investor-relations page names 7 research houses: Canaccord Genuity, Cowen & Co., Evercore ISI, H.C. Wainwright, Mizuho Securities, Rodman & Renshaw, LLC, and Stifel.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage is sealed. The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n10 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)\n- https://data.sec.gov/submissions/CIK0001604464.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/ATRA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://investors.atarabio.com/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/ATRA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm",
    "state": "sourced",
    "value": "DELOITTE & TOUCHE LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm",
    "state": "sourced",
    "value": "34"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm",
    "state": "sourced",
    "value": "San Francisco, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/ATRA",
  "coverage": {
   "count": 7,
   "houses": [
    {
     "analyst": "John Newman, Ph.D.",
     "house": "Canaccord Genuity",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Phil Nadeau, Ph.D.",
     "house": "Cowen & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Jonathan Miller, Ph.D.",
     "house": "Evercore ISI",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Robert Burns",
     "house": "H.C. Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Salim Syed",
     "house": "Mizuho Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Tony Butler, Ph.D.",
     "house": "Rodman & Renshaw, LLC",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Benjamin Burnett, Ph.D.",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://investors.atarabio.com/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://investors.atarabio.com/analyst-coverage",
     "result": "read: 7 of 8 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 176,
     "median_cadence_gap_days": 5.5,
     "median_filings": 65.5,
     "median_latency_days": 4,
     "name": "2836 Biological Products, (No Diagnostic Substances)"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "agm_egm": 2,
    "corporate_news": 5,
    "director_change": 2,
    "directors_dealings": 23,
    "halt_suspension": 1,
    "prospectus": 4,
    "regulatory_filing": 23,
    "results": 8
   },
   "cadence_median_gap_days": 3,
   "filing_days": 40,
   "filings": 69,
   "latency_days": 65,
   "latest": [
    {
     "category": "4",
     "date": "2026-09-04",
     "source": "https://www.sec.gov/Archives/edgar/data/1604464/000090514826004085/xslF345X06/form4.xml",
     "title": "4 — FORM 4",
     "type": "directors_dealings"
    },
    {
     "category": "144",
     "date": "2026-08-26",
     "source": "https://www.sec.gov/Archives/edgar/data/1604464/000090514826003961/xsl144X01/primary_doc.xml",
     "title": "144",
     "type": "regulatory_filing"
    },
    {
     "category": "4",
     "date": "2026-08-26",
     "source": "https://www.sec.gov/Archives/edgar/data/1604464/000090514826003960/xslF345X06/form4.xml",
     "title": "4 — FORM 4",
     "type": "directors_dealings"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-08-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1604464/000091957426005481/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "10-Q",
     "date": "2026-08-12",
     "source": "https://www.sec.gov/Archives/edgar/data/1604464/000119312526346885/atra-20260630.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-09-04",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ATRA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (ISINs mapped to the LEI)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest",
    "state": "sourced",
    "value": "US0465132068"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001604464.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US0465132068)",
    "state": "sourced",
    "value": "549300WBXUXZRE03MS38"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001604464.json",
    "state": "sourced",
    "value": "Atara Biotherapeutics, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001604464.json",
    "state": "sourced",
    "value": "2836 Biological Products, (No Diagnostic Substances)"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001604464.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "ATRA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:a6cf7e917bcb07ec3475c69b5478ca964d9fed6588003d7e6cb86701f1b3b4d0",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/ATRA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:a6cf7e917bcb07ec3475c69b5478ca964d9fed6588003d7e6cb86701f1b3b4d0",
 "path": "/us/NASDAQ/ATRA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Atara Biotherapeutics, Inc., listed on NASDAQ under ticker ATRA, with ISIN US0465132068 and LEI 549300WBXUXZRE03MS38. Its security type is Corporate, its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is United States, Delaware. Segment is not on the record. Status: listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 69 filings in the twelve months to 2026-11-08, across 40 filing days. The median gap between filing days is 3 days. Days from the latest filing to the record date are 65; the latest filing is dated 2026-09-04 and is of type directors_dealings. The NASDAQ exchange median is 52 filings, a median cadence gap of 6.0 days, and a median latency of 5.0 days. The sector median is 65.5 filings, a median cadence gap of 5.5 days, and a median latency of 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is DELOITTE & TOUCHE LLP, located in San Francisco, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name-change lines. Domicile change is not on the record: EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record: the exchanges' tier transfers are not EDGAR filings. Halt flag: listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The field was found. The issuer's investor-relations page names 7 research houses: Canaccord Genuity, Cowen & Co., Evercore ISI, H.C. Wainwright, Mizuho Securities, Rodman & Renshaw, LLC, and Stifel.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The vintage is sealed. The issuer's sealed years are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "10 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001604464.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/ATRA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1604464/000119312526108361/atra-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://investors.atarabio.com/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/ATRA"
  }
 ],
 "title": "Atara Biotherapeutics, Inc. (ATRA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}